Browse News
Filter News
Found 531 articles
-
One approach that is being developed by researchers at Stanford University leveraged nanoparticles. Preclinical research was recently published on it in the journal ACS Central Science.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 19, 2021.
-
Europe animal healthcare market size to amass USD 74 billion by 2026
1/18/2021
-
Johnson & Johnson published interim Phase I/IIa data in the New England Journal of Medicine showing its single-dose COVID-19 vaccine candidate created an immune response that lasted at least 71 days.
-
Janet Woodcock, the longtime director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration is set to take over the top spot of the regulatory agency on an interim basis following the presidential inauguration of Joe Biden.
-
ONK Therapeutics Appoints Hugh O’Dowd as Independent Chairman
1/14/2021
ONK Therapeutics Ltd, an innovative natural killer cell therapy company, announced that it has appointed Hugh O’Dowd as Director and independent Non-executive Chairman of its Board of Directors.
-
As the Pfizer-BioNTech COVID-19 vaccine is being evaluated by the U.S. FDA and the Moderna vaccine is soon to follow, here’s a look at several of the top COVID-19 vaccine candidates and where they stand as of today.
-
Slaoui will stay on as an adviser for one month. His resignation from the vaccine program was made at the request of the incoming Biden administration.
-
As is typical, the second day of the JP Morgan Annual Healthcare Conference—conducted virtually this year because of the pandemic—had plenty of news from the largest biopharma companies globally.
-
The U.S. Food and Drug Administration is experiencing abrupt and noticeable personnel changes as it continues to clash with the Health and Human Services, the department that oversees the agency and its operations.
-
Gilead is projecting remdesivir sales of about $2.825 billion alone for 2020.
-
BioSpace takes a look at some of the announcements that occurred Monday and will continue to update throughout the week.
-
Publicly-traded companies that have been heavily involved in developing therapies and vaccines for COVID-19 have seen significant spikes in their stock prices over the past 10 months, including Germany’s BioNTech, which has surged 187% in one year.
-
The advancing rollout of currently approved coronavirus disease 2019 (COVID-19) vaccines provides hope to many that existing lockdowns and social restrictions will soon be lifted, but experts suggest a “return to normal” likely won’t occur until herd immunity is achieved.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 12, 2021.
-
CPHO Issue Statement Series on COVID-19: mRNA Vaccines
1/10/2021
The end of 2020 marked a turning point for Canada in our fight against COVID-19. We witnessed Canadian approval of the first two vaccines for COVID-19 - the Pfizer-BioNTech vaccine and the Moderna vaccine, and rollout of initial doses of these vaccines across the country.
-
News, much of it good, keeps coming in about the efficacy of the various COVID-19 vaccines. Here’s a look.
-
Although yesterday’s media focus was on the riots at the U.S. Capitol, there was a fair amount of ongoing COVID-19 news. Here’s a look.
-
Keeping in mind that COVID-19 has dominated the news cycle, here are the top 10 stories of 2020 in no particular order.
-
Pfizer is giving itself a corporate facelift, dropping its traditional blue-pill company logo in favor of a double helix DNA spiral that reflects the advances in medical science that have placed the curing of multiple diseases within reach.